Providing researchers with unparalleled opportunity to access
novel endpoints
LONDON, July 10,
2024 /PRNewswire/ -- Healthcare
evidence-generation and technology company uMed have announced the
successful enrollment of over 2,000 participants into their
AccessCMD Cardiometabolic Cohort less than 4 months after starting
enrollment.
The exponential growth of the cohort within this short time
frame highlights the commitment of patients within this disease
area to engage in research, and showcases the effectiveness of
uMed's unique model in providing research access that has
previously been unavailable.
AccessCMD is a novel decentralised registry and integrated
clinical research platform, ethics committee-approved under a
master protocol framework. As with all uMed Cohorts, AccessCMD is
powered by the Company's ACCESS Research Platform which is
partnered with a vast network of healthcare institutions in the UK
and US. This enables rapid and targeted identification of patients
via their health record data, and engagement via SMS, email, letter
and phone, on behalf of their healthcare institution. Upon
invitation to the cohort, patients provide their consent to be
re-contacted for the collection of additional data or participate
in additional research studies.
Participants within AccessCMD actively contribute data from
their Electronic Medical Records (EMR), genetic tests, wearable
devices and patient-reported outcome surveys, offering an
unparalleled opportunity for researchers within this disease area
to access novel endpoints.
"From the rapid growth we have seen with AccessCMD it is
clear that patients are willing and eager to participate in
research, they just need to be provided the opportunity to do so,
and at uMed we are empowering this unique access. We achieve
this through a combination of tailored communication on behalf of
the patients' trusted healthcare provider, offering research
opportunities that are highly relevant to the individual's health
circumstances, and allowing patients to participate from the
comfort of their own home" commented Anil Jina, MD. Chief
Medical Officer at uMed.
With the rise in global obesity and related diseases,
cardiometabolic research is capturing the attention of research
groups as they work towards the development of new therapies and
tools to address this health crisis.
The potential for these therapies to benefit such a large
proportion of the population is evident, however a challenge for
researchers at all stages of the therapy lifecycle is the ability
to access the required data points from large enough representative
sub-cohorts.
Cardiometabolic disease describes numerous conditions, each
interacting through intricate pathways and mechanisms that vary
among individuals, many of which remain incompletely understood.
Therefore researchers are often faced with the obstacles of finding
a sufficient number of patients that meet their very specific study
criteria, and obtaining the necessary endpoints needed to answer
their research questions. Available databases and registries are
static, preventing the easy collection of custom data, and
site-based research is time consuming and expensive to set-up.
"We've seen the huge impact of recent therapeutic
developments within cardiometabolics, and for the many researchers
now entering this field, accessibility and speed are
key." commented Dr Matt Wilson,
CEO & Founder of uMed. "uMed is bridging the evidence
gaps that currently exist between static databases and site-based
studies, enabling the rapid collection of custom datasets without
the requirement to start studies from scratch. AccessCMD presents
researchers with a large cohort of pre-consented patients that
researchers can rapidly re-contact to access additional custom
endpoints to augment the expanding baseline dataset."
"The rate of growth of AccessCMD is compelling and the
potential for further growth is exciting. Over a quarter of
the population in the UK have risk factors, such high BMI, for
serious cardiometabolic diseases. uMed's integration with
healthcare institutions across the UK is providing access to a
large number of these patients. If we extrapolate the rate of
growth we are seeing in AccessCMD to these wider population
numbers, we expect to be able to improve access for patients to
relevant research studies and to present researchers with important
opportunities to extend their research to groups who have been
historically underserved." commented Dr Mark Toshner, Chief Investigator of
AccessCMD
AccessCMD is currently recruiting patients across the UK via
uMed's healthcare network, with plans to launch the Cohort in the
US by the end of 2024.
View original
content:https://www.prnewswire.com/news-releases/umeds-accesscmd-next-generation-cardiometabolic-cohort-hits-2000-patient-milestone-in-less-than-4-months-302191933.html
SOURCE uMed